Infliximab [Remicade®]: The magic bullet for Crohn's diseae?

Digestive and Liver Disease

Volumn 32, Issue 8, 2000, Pages 653-656

  D'Haens, G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CHIMERIC ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G1; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PARACETAMOL; PLACEBO; TUMOR NECROSIS FACTOR; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANAPHYLACTIC SHOCK; ARTICLE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCUTANEOUS FISTULA; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE OBSTRUCTION; INTESTINE RESECTION; LONG TERM CARE; PREOPERATIVE TREATMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SIDE EFFECT; STEROID THERAPY; SYMPTOMATOLOGY; TREATMENT OUTCOME; IMMUNOLOGY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033625835     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
2. Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
3. The role of tumor necrosis factor in health and disease
4. Location of tumor necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease
5. Construction and initial characterization of a mouse-human anti-TNF antibody
6. The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF-α lethality in vivo
7. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
8. A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor α for Crohn's disease
9. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
10. Endoscopic and histological healing with infliximab antibodies in Crohn's disease: A European multicenter trial
11. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
12. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
13. Duration of response following cessation of infliximab therapy for active and fisulizing Crohn's disease
14. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
15. Infliximab for the treatment of fistulas in patients with Crohn's disease
16. Infliximab (Remicade®) for treatment of perineal metastatic Crohn's disease
17. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients
18. Complete bowel obstruction following initial response to infliximab therapy: A series of a newly described complication
19. A multicenter study of Infliximab in the treatment of children with active Crohn's disease
20. Delayed hypersensitivity to infliximab (Remicade) infusion after 2-4 year interval without treatment